A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

RECRUITING

Identifier: CI-TRIAL-00114928
Entity page: /trial/NCT06764875 ↗
Edges: 8

Neighbours: 2 cancers6 drugs
Drawn: 8 of 8 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer condition of …CONDITION_OFderived2 of 2
← condition of	Gastroesophageal Junction Adenocarcinoma registry condition “Gastroesophageal Junction Adenocarcinoma” mapped ONTOLOGY_EXACT	—	—	Gastroesophageal Junction Adenocarcinoma	1	Observed	clinicaltrials	graph →
← condition of	HER2-Positive Gastric Adenocarcinoma

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer intervention of …INTERVENTION_OFderived6 of 6
← intervention of	Capecitabinesmall molecule registry intervention “Capecitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fluorouracilsmall molecule registry intervention “5-fluorouracil” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Oxaliplatinsmall molecule registry intervention “Oxaliplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Trastuzumabmonoclonal antibody registry intervention “Trastuzumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer intervention of …INTERVENTION_OFderived6 of 6

← intervention of

Capecitabinesmall molecule

registry intervention “Capecitabine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Cisplatinsmall molecule

registry intervention “Cisplatin” (DRUG) mapped ALIAS

—